GSK

News

GSK targets younger age group with RSV jab Arexvy

GSK has reported new clinical data pointing to a benefit with its respiratory syncytial virus (RSV) vaccine Arexvy when used to treat a younger age group than the over-60s

News

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years,

News

ViiV’s injectable HIV PrEP drug Apretude gets EU okay

People in the EU who need access to pre-exposure prophylaxis (PrEP) for HIV could soon have a new option with fewer doses after the European Commission approved ViiV Healt

News

GSK gets wide FDA approval for myelofibrosis drug

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquire

News

Malaria vaccine-drug combo achieves 'dramatic' results

Final results from a landmark study looking at the use of GSK's Mosquirix malaria vaccine alongside antimalarial drugs and other measures have shown a 90%-plus reduction i

News

One in five men carries HPV linked to cancer

Researchers have estimated that almost one in three men worldwide is infected with at least one genital human papillomavirus (HPV) strain, and one in five is harbouring st

GSK targets younger age group with RSV jab Arexvy

GSK to lean on Zhifei for Shingrix and maybe Arexvy in China

ViiV’s injectable HIV PrEP drug Apretude gets EU okay

GSK gets wide FDA approval for myelofibrosis drug

Malaria vaccine-drug combo achieves 'dramatic' results

One in five men carries HPV linked to cancer

Lilly's 'triple G' retatrutide aces crucial obesity trial

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks